Influenza A Viral Infections Drug Development Pipeline Review, 2018

Publisher Name :
Date: 30-Apr-2018
No. of pages: 188

This report provides an overview of the pipeline landscape for influenza A viral infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for influenza A H3N2, H1N1, H5N1 and H7N9 subtype infections, and features dormant and discontinued products.

Influenza is an acute infection of the respiratory tract that predominately affects the nose, throat and bronchi, and less commonly the lungs. Influenza viruses have a single-stranded segmented RNA genome. They belong to the family Orthomyxoviridae, and are categorized into three genera based on their core proteins – A, B and C. Influenza A and B viruses are responsible for the majority of symptomatic cases of influenza in humans.

Influenza A viruses can be further categorized based on their expression of two viral surface proteins: hemagglutinin (H); and neuraminidase (N). These viruses are known to have high mutation rates, with frequent changes to the viral protein structure.

Scope


  • Which companies are the most active within the pipeline for influenza A viral infections?

  • Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?

  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

  • What are the most important R&D milestones and data publications to have happened within this field?


Reasons to buy


  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Influenza A Viral Infections Drug Development Pipeline Review, 2018

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 8

2 Introduction 10
2.1 Influenza A Viral Infections Report Coverage 10
2.2 Influenza A Virus, H3N2 Subtype Infections – Overview 10
2.3 Influenza A Virus, H1N1 Subtype Infections – Overview 10
2.4 Influenza A Virus, H5N1 Subtype Infections – Overview 10
2.5 Influenza A Virus, H7N9 Subtype Infections – Overview 10

3 Therapeutics Development 11
3.1 Influenza A Virus, H3N2 Subtype Infections 11
3.2 Influenza A Virus, H1N1 Subtype Infections 19
3.3 Influenza A Virus, H5N1 Subtype Infections 31
3.4 Influenza A Virus, H7N9 Subtype Infections 41

4 Therapeutics Assessment 48
4.1 Influenza A Virus, H3N2 Subtype Infections 48
4.2 Influenza A Virus, H1N1 Subtype Infections 55
4.3 Influenza A Virus, H5N1 Subtype Infections 62
4.4 Influenza A Virus, H7N9 Subtype Infections 69

5 Companies Involved in Therapeutics Development 75
5.1 Influenza A Virus, H3N2 Subtype Infections 75
5.2 Influenza A Virus, H1N1 Subtype Infections 89
5.3 Influenza A Virus, H5N1 Subtype Infections 114
5.4 Influenza A Virus, H7N9 Subtype Infections 130

6 Dormant Projects 140
6.1 Influenza A Virus, H3N2 Subtype Infections 140
6.2 Influenza A Virus, H1N1 Subtype Infections 142
6.3 Influenza A Virus, H5N1 Subtype Infections 146
6.4 Influenza A Virus, H7N9 Subtype Infections 151

7 Discontinued Products 152
7.1 Influenza A Virus, H3N2 Subtype Infections 152
7.2 Influenza A Virus, H1N1 Subtype Infections 153
7.3 Influenza A Virus, H5N1 Subtype Infections 153

8 Product Development Milestones 154
8.1 Influenza A Virus, H3N2 Subtype Infections 154
8.2 Influenza A Virus, H1N1 Subtype Infections 160
8.3 Influenza A Virus, H5N1 Subtype Infections 174
8.4 Influenza A Virus, H7N9 Subtype Infections 185

9 Appendix 187
9.1 Methodology 187
9.2 Coverage 187
9.3 Secondary Research 187
9.4 Primary Research 187
9.5 Expert Panel Validation 187
9.6 Contact Us 188
9.7 Disclaimer 188

List of Tables

Table 1: Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections 11
Table 2: Number of Products under Development by Companies Influenza A Virus, H3N2 Subtype Infections 12
Table 3: Number of Products under Development by Universities/Institutes Influenza A Virus, H3N2 Subtype Infections 14
Table 4: Products under Development by Companies Influenza A Virus, H3N2 Subtype Infections 15
Table 5: Products under Development by Universities/Institutes Influenza A Virus, H3N2 Subtype Infections 18
Table 6: Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections 19
Table 7: Number of Products under Development by Companies, Influenza A Virus, H1N1 Subtype Infections 21
Table 8: Number of Products under Development by Universities/Institutes, Influenza A Virus, H1N1 Subtype Infections 23
Table 9: Products under Development by Companies, Influenza A Virus, H1N1 Subtype Infections 24
Table 10: Products under Development by Universities/Institutes, Influenza A Virus, H1N1 Subtype Infections 30
Table 11: Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections 32
Table 12: Number of Products under Development by Companies, Influenza A Virus, H5N1 Subtype Infections 34
Table 13: Number of Products under Development by Universities/Institutes, Influenza A Virus, H5N1 Subtype Infections 36
Table 14: Products under Development by Companies, Influenza A Virus, H5N1 Subtype Infections 37
Table 15: Products under Development by Universities/Institutes, Influenza A Virus, H5N1 Subtype Infections 40
Table 16: Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections 41
Table 17: Number of Products under Development by Companies, Influenza A Virus, H7N9 Subtype Infections 43
Table 18: Number of Products under Development by Universities/Institutes, Influenza A Virus, H7N9 Subtype Infections 44
Table 19: Products under Development by Companies, Influenza A Virus, H7N9 Subtype Infections 45
Table 20: Products under Development by Universities/Institutes, Influenza A Virus, H7N9 Subtype Infections 47
Table 21: Number of Products by Stage and Target, Influenza A Virus, H3N2 Subtype Infections 49
Table 22: Number of Products by Stage and Mechanism of Action, Influenza A Virus, H3N2 Subtype Infections 51
Table 23: Number of Products by Stage and Route of Administration, Influenza A Virus, H3N2 Subtype Infections 53
Table 24: Number of Products by Stage and Molecule Type, Influenza A Virus, H3N2 Subtype Infections 55
Table 25: Number of Products by Stage and Target, Influenza A Virus, H3N2 Subtype Infections 56
Table 26: Number of Products by Stage and Mechanism of Action, Influenza A Virus, H3N2 Subtype Infections 58
Table 27: Number of Products by Stage and Route of Administration, Influenza A Virus, H3N2 Subtype Infections 60
Table 28: Number of Products by Stage and Molecule Type, Influenza A Virus, H3N2 Subtype Infections 62
Table 29: Number of Products by Stage and Target, Influenza A Virus, H5N1 Subtype Infections 63
Table 30: Number of Products by Stage and Mechanism of Action, Influenza A Virus, H5N1 Subtype Infections 65
Table 31: Number of Products by Stage and Route of Administration, Influenza A Virus, H5N1 Subtype Infections 67
Table 32: Number of Products by Stage and Molecule Type, Influenza A Virus, H5N1 Subtype Infections 68
Table 33: Number of Products by Stage and Target, Influenza A Virus, H7N9 Subtype Infections 70
Table 34: Number of Products by Stage and Mechanism of Action, Influenza A Virus, H7N9 Subtype Infections 71
Table 35: Number of Products by Stage and Route of Administration, Influenza A Virus, H7N9 Subtype Infections 73
Table 36: Number of Products by Stage and Molecule Type, Influenza A Virus, H7N9 Subtype Infections 74
Table 37: Influenza A Virus, H3N2 Subtype Infections – Pipeline by AbbVie Inc 75
Table 38:  Influenza A Virus, H3N2 Subtype Infections – Pipeline by Adimmune Corp 76
Table 39: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Aphios Corp 76
Table 40: Influenza A Virus, H3N2 Subtype Infections – Pipeline by AusBio Ltd 77
Table 41: Influenza A Virus, H3N2 Subtype Infections – Pipeline by BioCryst Pharmaceuticals Inc 77
Table 42: Influenza A Virus, H3N2 Subtype Infections – Pipeline by BiondVax Pharmaceuticals Ltd 78
Table 43: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Cadila Healthcare Ltd 78
Table 44: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Celltrion Inc 79
Table 45: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Emergent BioSolutions Inc 80
Table 46: Influenza A Virus, H3N2 Subtype Infections – Pipeline by FluGen Inc 80
Table 47: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Inovio Pharmaceuticals Inc 81
Table 48: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd 81
Table 49: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Johnson & Johnson 82
Table 50: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Medicago Inc 83
Table 51: Influenza A Virus, H3N2 Subtype Infections – Pipeline by MedImmune LLC 83
Table 52: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Mucosis BV (Inactive) 84
Table 53: Influenza A Virus, H3N2 Subtype Infections – Pipeline by NanoViricides Inc 84
Table 54: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Novavax Inc 85
Table 55: Influenza A Virus, H3N2 Subtype Infections – Pipeline by OPKO Health Inc 85
Table 56: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Sanofi 86
Table 57: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Sanofi Pasteur SA 87
Table 58: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Sarepta Therapeutics Inc 87
Table 59: Influenza A Virus, H3N2 Subtype Infections – Pipeline by SK Chemicals Co Ltd 88
Table 60: Influenza A Virus, H3N2 Subtype Infections – Pipeline by VBI Vaccines Inc 88
Table 61: Influenza A Virus, H1N1 Subtype Infections – Pipeline by AbbVie Inc 89

List of Figures

Figure 1: Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections 11
Figure 2: Number of Products under Development by Companies, Influenza A Virus, H3N2 Subtype Infections 12
Figure 3: Number of Products under Development by Universities/Institutes Influenza A Virus, H3N2 Subtype Infections 14
Figure 4: Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections 19
Figure 5: Number of Products under Development by Companies, Influenza A Virus, H1N1 Subtype Infections 20
Figure 6: Number of Products under Development by Universities/Institutes, Influenza A Virus, H1N1 Subtype Infections 23
Figure 7: Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections 31
Figure 8: Number of Products under Development by Companies, Influenza A Virus, H5N1 Subtype Infections 33
Figure 9: Number of Products under Development by Universities/Institutes, Influenza A Virus, H5N1 Subtype Infections 36
Figure 10: Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections 41
Figure 11: Number of Products under Development by Companies, Influenza A Virus, H7N9 Subtype Infections 42
Figure 12: Number of Products under Development by Universities/Institutes, Influenza A Virus, H7N9 Subtype Infections 44
Figure 13: Number of Products by Top 10 Targets, Influenza A Virus, H3N2 Subtype Infections 48
Figure 14: Number of Products by Stage and Top 10 Targets, Influenza A Virus, H3N2 Subtype Infections 48
Figure 15: Number of Products by Top 10 Mechanism of Actions, Influenza A Virus, H3N2 Subtype Infections 50
Figure 16: Number of Products by Stage and Top 10 Mechanism of Actions, Influenza A Virus, H3N2 Subtype Infections 50
Figure 17: Number of Products by Routes of Administration, Influenza A Virus, H3N2 Subtype Infections 52
Figure 18: Number of Products by Stage and Routes of Administration, Influenza A Virus, H3N2 Subtype Infections 52
Figure 19: Number of Products by Top 10 Molecule Types, Influenza A Virus, H3N2 Subtype Infections 54
Figure 20: Number of Products by Stage and Top 10 Molecule Types, Influenza A Virus, H3N2 Subtype Infections 54
Figure 21: Number of Products by Top 10 Targets, Influenza A Virus, H3N2 Subtype Infections 55
Figure 22: Number of Products by Stage and Top 10 Targets, Influenza A Virus, H3N2 Subtype Infections 56
Figure 23: Number of Products by Top 10 Mechanism of Actions, Influenza A Virus, H3N2 Subtype Infections 57
Figure 24: Number of Products by Stage and Top 10 Mechanism of Actions, Influenza A Virus, H3N2 Subtype Infections 57
Figure 25: Number of Products by Top 10 Routes of Administration, Influenza A Virus, H3N2 Subtype Infections 59
Figure 26: Number of Products by Stage and Top 10 Routes of Administration, Influenza A Virus, H3N2 Subtype Infections 59
Figure 27: Number of Products by Top 10 Molecule Types, Influenza A Virus, H3N2 Subtype Infections 61
Figure 28: Number of Products by Stage and Top 10 Molecule Types, Influenza A Virus, H3N2 Subtype Infections 61
Figure 29: Number of Products by Top 10 Targets, Influenza A Virus, H5N1 Subtype Infections 62
Figure 30: Number of Products by Stage and Top 10 Targets, Influenza A Virus, H5N1 Subtype Infections 63
Figure 31: Number of Products by Top 10 Mechanism of Actions, Influenza A Virus, H5N1 Subtype Infections 64
Figure 32: Number of Products by Stage and Top 10 Mechanism of Actions, Influenza A Virus, H5N1 Subtype Infections 64
Figure 33: Number of Products by Routes of Administration, Influenza A Virus, H5N1 Subtype Infections 66
Figure 34: Number of Products by Stage and Routes of Administration, Influenza A Virus, H5N1 Subtype Infections 66
Figure 35: Number of Products by Top 10 Molecule Types, Influenza A Virus, H5N1 Subtype Infections 67
Figure 36: Number of Products by Stage and Top 10 Molecule Types, Influenza A Virus, H5N1 Subtype Infections 68
Figure 37: Number of Products by Targets, Influenza A Virus, H7N9 Subtype Infections 69
Figure 38: Number of Products by Stage and Targets, Influenza A Virus, H7N9 Subtype Infections 69
Figure 39: Number of Products by Mechanism of Actions, Influenza A Virus, H7N9 Subtype Infections 70
Figure 40: Number of Products by Stage and Mechanism of Actions, Influenza A Virus, H7N9 Subtype Infections 71
Figure 41: Number of Products by Routes of Administration, Influenza A Virus, H7N9 Subtype Infections 72
Figure 42: Number of Products by Stage and Routes of Administration, Influenza A Virus, H7N9 Subtype Infections 72
Figure 43: Number of Products by Molecule Types, Influenza A Virus, H7N9 Subtype Infections 73
Figure 44: Number of Products by Stage and Molecule Types, Influenza A Virus, H7N9 Subtype Infections 74

  • Global Cephalosporin Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 109
    Cephalosporin is an antibiotic medication commonly prescribed to treat several different types of infections. Cephalosporin originally derived from The fungus Acremonium, which was previously known as "Cephalosporium". The global Cephalosporin market was valued at US$ 1380.7 million in 2023 and is anticipated to reach US$ 1346.9 million by 2030, witnessing a CAGR of -0.3% during The forecast period 2024-2030. Market competition is intense. Qilu Antibiotics, Nectar Lifes......
  • Global Polymixin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 120
    According to our LPI (LP Information) latest study, the global Polymixin market size was valued at US$ 229.9 million in 2023. With growing demand in downstream market, the Polymixin is forecast to a readjusted size of US$ 291 million by 2030 with a CAGR of 3.4% during review period. The research report highlights the growth potential of the global Polymixin market. Polymixin are expected to show stable growth in the future market. However, product differentiation, reducing costs, and sup......
  • Global Sepsis Partnering Market Research Report 2024
    Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The Sepsis Partnering market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sepsis Partnering market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape......
  • Global Cephalosporin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 156
    According to our LPI (LP Information) latest study, the global Cephalosporin market size was valued at US$ 1350.7 million in 2023. With growing demand in downstream market, the Cephalosporin is forecast to a readjusted size of US$ 1319.6 million by 2030 with a CAGR of -0.3% during review period. The research report highlights the growth potential of the global Cephalosporin market. Cephalosporin are expected to show stable growth in the future market. However, product differentiation, re......
  • Global Amoxicillin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 127
    According to our LPI (LP Information) latest study, the global Amoxicillin market size was valued at US$ 4512.7 million in 2023. With growing demand in downstream market, the Amoxicillin is forecast to a readjusted size of US$ 5711.7 million by 2030 with a CAGR of 3.4% during review period. The research report highlights the growth potential of the global Amoxicillin market. Amoxicillin are expected to show stable growth in the future market. However, product differentiation, reducing co......
  • Global Metronidazole Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 136
    According to our LPI (LP Information) latest study, the global Metronidazole market size was valued at US$ 110.5 million in 2023. With growing demand in downstream market, the Metronidazole is forecast to a readjusted size of US$ 106.6 million by 2030 with a CAGR of -0.5% during review period. The research report highlights the growth potential of the global Metronidazole market. Metronidazole are expected to show stable growth in the future market. However, product differentiation, redu......
  • Global Drugs for Herpes Labialis (Oral Herpes) Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 131
    According to our LPI (LP Information) latest study, the global Drugs for Herpes Labialis (Oral Herpes) market size was valued at US$ 2404.5 million in 2023. With growing demand in downstream market, the Drugs for Herpes Labialis (Oral Herpes) is forecast to a readjusted size of US$ 3402.2 million by 2030 with a CAGR of 5.1% during review period. The research report highlights the growth potential of the global Drugs for Herpes Labialis (Oral Herpes) market. Drugs for Herpes Labialis (Ora......
  • Global Ampicillin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 93
    According to our LPI (LP Information) latest study, the global Ampicillin market size was valued at US$ 161.6 million in 2023. With growing demand in downstream market, the Ampicillin is forecast to a readjusted size of US$ 194.7 million by 2030 with a CAGR of 2.7% during review period. The research report highlights the growth potential of the global Ampicillin market. Ampicillin are expected to show stable growth in the future market. However, product differentiation, reducing costs, a......
  • Global Acinetobacter Infections Treatment Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 101
    According to our LPI (LP Information) latest study, the global Acinetobacter Infections Treatment market size was valued at US$ million in 2023. With growing demand in downstream market, the Acinetobacter Infections Treatment is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Acinetobacter Infections Treatment market. Acinetobacter Infections Treatment are expected to show stable ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs